- Eurofins CDMO Alphora’s Canadian division has received advisory services and funding from NRC IRAP to support an R&D collaboration on next-generation ADC production.
- The project focuses on developing a high-yield expression platform to simplify and accelerate antibody-drug conjugate manufacturing.
Eurofins CDMO Alphora said its Canadian-based division is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program to support a research and development collaboration focused on next-generation antibody-drug conjugate production. The project aims to address growing demand for targeted therapeutics through a new manufacturing approach.
As part of the initiative, Eurofins CDMO Alphora (Canada) is collaborating with Daresbury Proteins Ltd. to contribute development and contract manufacturing expertise to the NextGen ADC Platform project. The collaboration centers on engineering high-yield expression vectors and peptide linker tags for advanced ADC production.
The project is designed to develop a novel expression platform that integrates optimized affinity peptide tags directly into monoclonal antibody production. According to the announcement, this approach is intended to streamline ADC manufacturing by removing several traditional conjugation and purification steps.
Eurofins CDMO Alphora said the resulting process is expected to reduce manufacturing complexity and costs while accelerating development timelines. The initiative also aims to support future production of clinic-ready ADCs suitable for point-of-care reconstitution.
By combining Eurofins CDMO Alphora’s capabilities in complex drug development and contract manufacturing with specialized protein expression technology from Daresbury Proteins and support from NRC IRAP, the project is intended to advance innovation, support skilled job creation, and strengthen Canada’s capacity in precision biologics manufacturing.
